Appointment Icon

UnityPoint Clinic - Express (Ankeny)

1055 Southwest Oralabor Road
Ankeny, IA 50023

Current Estimated Wait:
Closed

UnityPoint Clinic - Express (Jordan Creek)

180 Jordan Creek Pkwy
West Des Moines, IA 50266

Current Estimated Wait:
Closed

UnityPoint Clinic - Express (Waukee)

950 E Hickman Rd
Waukee, IA 50263

Current Estimated Wait:
Closed

UnityPoint Clinic Behavioral Health Urgent Care - Des Moines

1250 East 9th Street
Des Moines, IA 50316

Current Estimated Wait:
Closed

UnityPoint Clinic Urgent Care - Altoona

2720 8th Street Southwest
Altoona, IA 50009

Current Estimated Wait:
Closed

UnityPoint Clinic Urgent Care - Ankeny Medical Park

3625 North Ankeny Boulevard
Ankeny, IA 50023

Current Estimated Wait:
Closed

UnityPoint Clinic Urgent Care - Ingersoll

2103 Ingersoll Avenue
Des Moines, IA 50312

Current Estimated Wait:
Closed

UnityPoint Clinic Urgent Care - Lakeview

6000 University Avenue
West Des Moines, IA 50266

Current Estimated Wait:
Closed

UnityPoint Clinic Urgent Care - Southglen

6520 Southeast 14th Street
Des Moines, IA 50320

Current Estimated Wait:
Closed

UnityPoint Clinic Urgent Care - Urbandale

5200 NW 100th Street
Urbandale, IA 50322

Current Estimated Wait:
Closed
Blank Children's Hospital

Pediatric Hematology/Oncology Clinical Trials

Central Nervous System

ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

ACNS1831: A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 Associated Low-Grade Glioma

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma not associated with BRAFV600E Mutations or Systemic (NF1)

Leukemia

AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant ALL

AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-ALL

AALL1631: International Phase 3 Trial in Philadelphia. Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

AALL1731: A Phase 3 Trial Investigating Blinatumomab  in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-ALL and the Treatment of Patients with Localized B-LLy

AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy

AALL1821: A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

AAML1921: A Phase 1/2 Study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia

Lymphoma

AALL1731: A Phase 3 Trial Investigating Blinatumomab  in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-ALL and the Treatment of Patients with Localized B-LLy

AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy

S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Germ Cell

AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors. 

Hepatic Malignancy

AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial

Neuroblastoma

ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma. 

ANBL1821: A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma.

Renal Tumors

AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Sarcoma

ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide Alternating with Vincristine and Irinotecan Versus VAC/VI Plus Temsirolimus in Patients with Intermediate Risk Rhabdomyosarcoma

Match Trial

APEC1621 SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

APEC1621 A: Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions

APEC1621 B: Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations

APEC1621 D: Phase 2 subprotocol of LY3023414 in Solid Tumors

APEC1621 F: Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

APEC1621 G: Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

APEC1621 H: Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

APEC1621 I: Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

APEC1621 K: Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations

APEC1621 M: Phase 2 Subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations

APEC1621 N: Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations

Registry, Biology & Banking

APEC14B1: Project: EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

ANBL00B1: Neuroblastoma Classification Biology Studies

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

POCC: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19

Cancer Control

ACCL10P1: Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study

Survivorship/Late Effects

ALTE03N1: Key Adverse Events after Childhood Cancer

ALTE05N1: Umbrella Long-term Follow-up Protocol

ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

ALTE16C1: Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in AYA Survivors of Osteosarcoma

ALTE2031: StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors

Cancer Care Delivery Research

ACCL16N1CD: Documentation and Delivery of Guideline-Consistent Treatment in AYA ALL

Sponsored Trials

IM2008-006: Severe Chronic Neutropenia International Registry

SPARK: Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial

Clinical Trial Resources